What Fiberlab does

Fiberlab Biotech, founded in 2016 and privately held, is a U.S.-based manufacturer of pharmaceutical-grade cannabinoid acid isolates and condition-specific compound formulas, operating with 1–10 employees and a registered presence in Austin, TX. The company's core technology is a proprietary cryogenic (non-CO2) closed-loop extraction process combined with a six-step manufacturing workflow — extraction, winterization, decarboxylation, isolation, purification, and quality verification — designed to preserve cannabinoid acid integrity and achieve a stated 99.9%+ purity standard with zero residual solvents. All products undergo multi-method third-party verification, including HPLC-UV/LC-MS, GC-MS Headspace, ICP-MS, qPCR/Culture, and LC-MS/MS testing, with 100% COA coverage across the catalog.

The product portfolio is organized around five acid isolates (THCA, CBDA, CBGA, CBCA, CBNA) at 99.9%+ purity and four proprietary compound formulas — NeuroCalm (FC-N01), Serenity (FC-S02), Oncology Support (FC-O03), and Inflammation Protocol (FC-I04) — each blended for specific therapeutic indications including neurological disorders, chronic pain, PTSD, oncology support, and inflammation. Two delivery devices, a Cannabinoid Nasal Spray (10 mL, 100 doses) and a Cannabinoid Inhaler, extend the portfolio into rapid-onset pulmonary and intranasal administration.

Fiberlab generates revenue through physician-priced sales of its isolates, compound formulas, and delivery devices, distributed exclusively through a network of 6+ licensed compounding pharmacies across 4 states (AZ, CO, TN, TX). The go-to-market is sales-led and physician-directed, with inquiries routed through a clinical affairs team that provides same-day response to physicians and 1–5 business day response to pharmacies, patients, and researchers. Pricing is quote-based and not publicly disclosed; a 2026 strategic pivot and the launch of the CannapūrRx sub-brand signal an ongoing portfolio repositioning.

Name

Fiberlab

Legal name

Fiberlab Biotech

Website

https://fiberlab.io

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Fiberlab Biotech is a U.S. manufacturer of pharmaceutical-grade cannabinoid acid isolates (THCA, CBDA, CBGA, CBCA, CBNA) at 99.9%+ purity and condition-specific compound formulas, distributed exclusively through licensed compounding pharmacies serving physician-directed clinical protocols.

Ownership category

akta.pro rank

Product category

Pharmaceutical Cannabinoid Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical cannabinoid isolates
• Cannabinoid compound formulas
• Cryogenic extraction processing
• Compounding pharmacy supply
• Purity verified cannabinoids

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Cannabinoid Product Sales: Sale of pharmaceutical-grade cannabinoid isolates (THCA, CBDA, CBGA, CBCA, CBNA) and compound formulas through licensed compounding pharmacy partners. Physician pricing model with quote-based inquiry process.
2. Clinical Consultation Services: Clinical affairs team provides support for physicians, pharmacies, patients, and researchers. Response times vary by inquiry type: physicians receive same-day response, others within 1-5 business days.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Fiberlab manufactures pharmaceutical-grade cannabinoid acid isolates (THCA, CBDA, CBGA, CBCA, CBNA) at 99.9%+ purity using a proprietary cryogenic non-CO2 extraction and six-step manufacturing process with multi-method third-party verification. The company also blends these isolates into four condition-specific compound formulas (NeuroCalm, Serenity, Oncology Support, Inflammation Protocol) and produces two delivery devices (nasal spray and pulmonary inhaler). All products are distributed exclusively through a physician-directed model via licensed compounding pharmacies across AZ, CO, TN, and TX.

Product overview

Fiberlab Biotech offers a portfolio of pharmaceutical-grade cannabinoid acid products built around five core isolate types (THCA, CBDA, CBGA, CBCA, CBNA) at 99.9%+ purity, supplemented by four proprietary compound formulas (NeuroCalm, Serenity, Oncology Support, Inflammation Protocol) that blend multiple isolates for specific therapeutic indications. The company also manufactures two delivery devices — a nasal spray and an inhaler — designed for rapid-onset cannabinoid delivery. All products are manufactured using cryogenic extraction and are distributed exclusively through a network of licensed compounding pharmacies.

Differentiator

Problem solved

Functional benefit

Brands

• CannapūrRx: Pharmaceutical-grade cannabinoid brand offering isolates and compound formulas for clinical applications including neurological disorders, chronic pain, PTSD, oncology support, and inflammation.

Products and services

• THCA Isolate Tetrahydrocannabinolic acid in its purest pharmaceutical form — a 99.9%+ pure crystalline powder isolate with neuroprotective, anti-inflammatory, and anti-nausea properties, precisely dosed for clinical micro-dosing protocols. Sold to licensed physicians and compounding pharmacies.
• CBDA Isolate Cannabidiolic acid isolate at 99.9%+ purity featuring serotonin-modulating properties, formulated for patients managing anxiety, PTSD, and treatment-related nausea. Sold to licensed physicians and compounding pharmacies.
• CBGA Isolate The 'mother cannabinoid' isolate at 99.9%+ purity, the biosynthetic precursor to all major cannabinoids, supporting metabolic function and serving as the foundation of compound formulas, with antibacterial properties. Sold to licensed physicians and compounding pharmacies.
• CBCA Isolate Cannabichromenic acid isolate at 99.9%+ purity with research-supported roles in neurogenesis and antimicrobial activity, a key component in neurological disorder protocols. Sold to licensed physicians and compounding pharmacies.
• CBNA Isolate Cannabinolic acid isolate at 99.9%+ purity with sedative and appetite-stimulating properties, integral to oncology support and chronic pain compound formulas. Sold to licensed physicians and compounding pharmacies.
• NeuroCalm Formula (FC-N01) A precision-blended compound formula combining THCA, CBCA, and CBGA isolates, targeting neuroprotection and pain modulation for patients with epilepsy, MS, Parkinson's, and neuropathic pain. Sold to physicians and compounding pharmacies.
• Serenity Formula (FC-S02) Compound formula combining serotonin-modulating CBDA with calming CBNA, designed for patients navigating PTSD and anxiety disorders. Sold to physicians and compounding pharmacies.
• Oncology Support Formula (FC-O03) A comprehensive adjunct formula combining THCA, CBDA, CBNA, and CBGA for patients in active cancer treatment, addressing nausea, appetite loss, pain, and inflammation with a full-spectrum cannabinoid acid blend. Sold to physicians and compounding pharmacies.
• Inflammation Protocol (FC-I04) Targeted anti-inflammatory formula combining THCA, CBCA, and CBGA for systemic and localized inflammation, suitable for autoimmune conditions, arthritis, and post-surgical recovery. Sold to physicians and compounding pharmacies.
• Cannabinoid Nasal Spray Advanced nasal delivery device providing 99.9%+ pure THC for rapid systemic absorption with precision dosing. 10 mL container providing 100 doses, no artificial flavors, colors, or preservatives, manufactured in GMP-certified facilities. Sold at physician pricing via inquiry.
• Cannabinoid Inhaler Pulmonary delivery device providing pharmaceutical-grade 99.9%+ pure THC for targeted, fast-acting relief directly to the respiratory system with no combustion and no solvents. Sold at physician pricing via inquiry.

Quantifiable outcome

• 99.9%+ pharmaceutical purity achieved across all cannabinoid isolates
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core.

• Austin Compounding PharmacycoreChannel Partner/ Reseller/ DistributorLicensed compounding pharmacy in Austin, TX (1200 S Lamar Blvd). Dispenses THCA, CBDA, CBGA isolates and NeuroCalm, Serenity compound formulas. Accepting new patients. Hours: Mon-Fri 9am-6pm, Sat 10am-3pm.
• Houston Medical CompounderscoreChannel Partner/ Reseller/ DistributorLicensed compounding pharmacy in Houston, TX (4500 Bissonnet St). Dispenses THCA, CBCA, CBNA isolates and Oncology Support, Inflammation Protocol formulas. Accepting new patients. Hours: Mon-Fri 8am-7pm, Sat 9am-4pm.
• Dallas Precision PharmacycoreChannel Partner/ Reseller/ DistributorLicensed compounding pharmacy in Dallas, TX (6750 Hillcrest Ave). Dispenses CBDA, CBGA isolates and Serenity, NeuroCalm compound formulas. Accepting new patients. Hours: Mon-Fri 9am-5:30pm.
• Denver Integrative CompoundingcoreChannel Partner/ Reseller/ DistributorLicensed compounding pharmacy in Denver, CO (2100 E Colfax Ave). Dispenses all five isolates (THCA, CBDA, CBCA, CBNA, CBGA) and all four compound formulas. Accepting new patients. Hours: Mon-Fri 8:30am-6pm, Sat 10am-2pm.
• Phoenix Clinical PharmacycoreChannel Partner/ Reseller/ DistributorLicensed compounding pharmacy in Phoenix, AZ (3300 N Central Ave). Dispenses THCA, CBGA isolates and Inflammation Protocol, Oncology Support formulas. Currently on waitlist. Hours: Mon-Fri 9am-6pm.
• Nashville Compounding CentercoreChannel Partner/ Reseller/ DistributorLicensed compounding pharmacy in Nashville, TN (1800 Church St). Dispenses CBDA, CBNA isolates and Serenity, NeuroCalm compound formulas. Accepting new patients. Hours: Mon-Fri 9am-5pm.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Charlotte's Web Holdings: Charlotte's Web makes proprietary hemp-derived cannabinoid extracts targeting specific wellness and clinical use cases (sleep, calm, recovery) with branded product lines. Its vertically integrated cultivation-to-extract model and indication-focused product framing parallels Fiberlab's condition-specific compound formulas.
• Elixinol Wellness: Elixinol produces premium, third-party-tested hemp-derived CBD oils and capsules for both practitioner and consumer channels. Comparable to Fiberlab as a smaller, quality-focused cannabinoid producer targeting health professional and pharmacy distribution.
• Medical Marijuana Inc. Medical Marijuana Inc. operates a portfolio of hemp-derived CBD and cannabinoid brands including HempMeds and Kannaway, with a strong physician/direct-selling channel orientation. Comparable to Fiberlab in the niche of smaller, specialist cannabinoid companies building branded product portfolios around clinical/endorsement positioning.
• MediPharm Labs: MediPharm Labs is a Canadian B2B manufacturer of pharmaceutical-grade cannabinoid APIs, extracts, and concentrates supplied to other producers and clinicians. Like Fiberlab, it focuses on wholesale purified inputs rather than retail consumer products, making it a directly comparable pharma-grade cannabinoid API supplier.
• CV Sciences: CV Sciences develops and sells pharmaceutical-grade CBD products (e.g., its PlusCBDOil brand) with a GRAS-pending, cGMP-manufactured positioning. It is comparable to Fiberlab in its focus on pharmaceutical-grade, third-party-tested cannabinoid inputs over commodity-grade market positioning.

Broad incumbents

• Aurora Cannabis: Aurora Cannabis operates a vertically integrated cannabinoid platform including GMP-certified production and medical cannabis distribution across multiple countries. Its broad medical/recreational footprint and GMP positioning make it a useful incumbent benchmark for Fiberlab's physician-channel ambitions.
• Canopy Growth: Canopy Growth produces both medical and consumer cannabinoid products through brands like Spectrum Therapeutics, with strong GMP and pharmaceutical partnerships. Comparable to Fiberlab as a broad incumbent serving a physician/cannabinoid-medicine channel at meaningful scale.
• Cronos Group: Cronos Group is a global cannabinoid operator with branded consumer products and a strategic partnership with a major pharma for cannabinoid therapeutic R&D. Relevant as a broad incumbent with pharma ambitions in the same therapeutic-category landscape Fiberlab targets.
• Jazz Pharmaceuticals: Jazz Pharmaceuticals acquired GW Pharmaceuticals, gaining FDA-approved cannabinoid drugs Epidiolex and Sativex. As the only large-cap pharma with approved cannabinoid therapeutics, Jazz is the reference incumbent for the pharmaceutical-grade cannabinoid specialty Fiberlab targets via the physician/compounding channel.
• Tilray Brands: Tilray is a large diversified cannabis operator with a pharmaceutical division (Tilray Medical) distributing GMP-produced cannabinoid products globally. It is comparable to Fiberlab as a broad incumbent with pharma-grade offerings across multiple international markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/fiberlabinc
• LinkedInlinkedin.com/company/fiberlab

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fiberlab